Existing and potential therapeutic approaches targeting peroxisome proliferator-activated receptors in the management of Type 2 diabetes

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 12, 2006, Pages 1713-1733

  Stefanski, Adam ^a   Majkowska, Liliana ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Peroxisome proliferator activated receptor; Type 2 diabetes

Indexed keywords

2 [4 [2 [3 (2,4 DIFLUOROPHENYL) 1 HEPTYLUREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; AVE 0847; BALAGLITAZONE; BEZAFIBRATE; CARBOHYDRATE; DRG 2519; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GW 677954; IMIGLITAZAR; LBM 642; LIPID; LY 518674; MC 555; METAGLIDASEN; METFORMIN; MURAGLITAZAR; NETOGLITAZONE; NS 220; ONO 5129; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PGX 510; PIOGLITAZONE; PLACEBO; PLX 204; ROSIGLITAZONE; TAK 654; TESAGLITAZAR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROSCLEROSIS; BONE MARROW DISEASE; CARCINOGENICITY; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL METABOLISM; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG USE; DYSLIPIDEMIA; EDEMA; HEART INFARCTION; HIGH THROUGHPUT SCREENING; HUMAN; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; STROKE; TRANSCRIPTION REGULATION; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 33845906385     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.12.1713     Document Type: Review

References (130)

1. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352:837-853.
2. OHKUBO Y, KISHIKAWA H, ARAKI E et al.: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. (1995) 28:103-117.
3. NATHAN DM, BUSE JB, DAVIDSON MB et al.: Management of hyperglycaemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. (2006) 49:1711-1721.
4. HAFFNER SM, ALEXANDER CM, COOK TJ et al.: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch. Intern. Med. (1999) 159:2661-2667.
5. PYORALA K, PEDERSEN TR, KJEKSHUS J et al.: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care (1997) 20:614-620.
6. SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. (1996) 335:1001-1009.
7. UK PROSPECTIVE DIABETES STUDY GROUP: Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. BMJ (1998) 317:703-713.
8. ADLER AI, STRATTON IM, NEIL HA et al.: Association of systolic blood pressure with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 36): prospective observational study. BMJ (2000) 321:412-419.
9. HOPE STUDY AND MICRO-HOPE SUBSTUDY. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet (2000) 355:253-259.
10. GAEDE P, VEDEL P, PARVING HH et al.: Intensified multifactorial intervention in patients with Type 2 diabetes mellitus and microalbuminuria: the StenoType 2 randomised study. Lancet (1999) 353:617-622.
11. OLIVARIUS NF, BECK-NIELSEN H, ANDREASEN AH et al. Randomised controlled trial of structured personal care of Type 2 diabetes mellitus. BMJ (2001) 323:970-9755.
12. HANEFELD M, FISCHER S, SCHMECHEL H et al.: Diabetes Intervention Study: multi-intervention trial in newly diagnosed NIDDM. Diabetes Care (1991) 14:308-317.
13. JOSS N, FERGUSON C, BROWN C et al.: Intensified treatment of patients with Type 2 diabetes mellitus and overt nephropathy. QJM (2004); 97:219-927.
14. VAMECQ J, DRAYE JP: Pathophysiology of peroxisomal β-oxidation. Essays Biochem. (1989) 24:115-225.
15. KLIEWER SA, XU HE, LAMBERT MH et al.: Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog. Horm. Res. (2001) 56:239-263.
16. ISSEMANN I, GREEN S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (1990) 347:645-650
17. SHER T, YI HF, MCBRIDE OW et al.: cDNA cloning, chromosomal mapping and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry (1993) 32:5598-5604.
18. LEONE TC, WEINHEIMER CJ, KELLY DP: A critical role for the peroxisome proliferator-activated receptor-α (PPAR-α) in the cellular fasting response: the PPAR-α-null mouse as a model of fatty acid oxidation disorders. Proc. Natl. Acad. Sci. USA (1999) 96:7473-7478.
19. FINCK BN, BERNAL-MIZRACHI C, HAN DH et al.: A potential link between muscle peroxisome proliferator-activated receptor-α signaling and obesity-related diabetes. Cell Metab. (2005) 1:133-44.
20. GUERRE-MILLO M, GERVOIS P, RASPE E et al.: Peroxisome proliferator-activated receptor-α activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. (2000) 275:16638-16642.
21. SUGDEN MC, HOLNESS MJ: Potential role of peroxisome proliferator-activated receptor-α in the modulation of glucose-stimutated insulin secretion. Diabetes (2004) 53:S71-S81.
22. LEFEBVRE P, CHINETTI G, FRUCHART JC et al.: Sorting out the roles of PPAR-α in energy metabolism and vascular homeostasis. J. Clin. Invest. (2006) 116:571-580.
23. ELBRECHT A, CHEN Y, CULLINAN CA et al.: Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors-γ1 and -γ2. Biochem. Biophys. Res. Commun. (1996) 224:431-437.
24. FAJAS L, AUBOEUF D, RASPE E et al.: The organization, promoter analysis and expression of the human PPAR-γ gene. J. Biol. Chem. (1997) 272:18779-18789.
25. FAJAS L, FRUCHART JC, AUWERX J: PPAR-γ3 mRNA: a distinct PPAR-γ mRNA subtype transcribed from an independent promoter. FEBS Lett. (1998) 438:55-60.
26. DESVERGNE B, WAHLI W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. (1999) 20:649-688.
27. PASCERI V, WU HD, WILLERSON JT et al.: Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated recepror-γ activators. Circulation (2000) 101:235-238.
28. WANG Y-X, LEE C-H, TIEP S et al.: Peroxisome-proliferator-activated receptur-δ activates far metabolism to prevent obesity. Cell (2003) 113:159-170.
29. TANAKA T, YAMAMOTO J, IWASAKI S et al.: Activation of peroxisome proliferators activated receptor-δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. USA (2003) 100:15924-15929.
30. BEDU E, WAHLI W, DESVERGNE B. Peroxisome proliferator-activated receptor-β/δ as a therapeutic target for metabolic diseases. Expert Opin. Ther. Targets (2005) 9:861-873.
31. LEE CH, OLSON P, HAVENER A et al.: PPAR-δ regulates glucose metabolism and insulin sensitivity. Proc. Natl. Acad. Sci. USA (2006) 103:3444-3449.
32. BARISH GD, NARKAR VA, EVANS RM: PPAR-δ: a dagger in the heart of the metabolic syndrome. J. Clin. Invest. (2006) 116:590-597.
33. KOH EH, KIM MS, PARK JY et al.: Peroxisome proliferator-activated receptor (PPAR)-α activation prevents diabetes in OLETF rats: comparison with PPAR-γ activation. Diabetes (2003) 52:2331-2337.
34. BERGERON R, YAO J, WOODS JW et al.: PPAR-α agonism prevents the onset of Type 2 diabetes in ZDF rats: a comparison to PPAR-α agonism. Endocrinology (2006) 147:4252-4262.
35. KIM H, HALUZIK M, ASGHAR Z et al.: Peroxisome proliferator-activated receptor-α agonist treatment in a transgenic model of Type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes (2003) 52:1770-1778.
36. LALLOYER F, VANDEWALLE B, PERCEVAULT F et al.: Peroxisome proliferator-activated receptor-α improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets. Diabetes (2006) 55:1605-1613
37. KOBAYASHI M, SHIGETA Y, HIRATA Y et al.: Improvement of glucose tolerance in NIDDM by clofibrate: randomized double-blind study. Diabetes Care (1988) 11:495-499.
38. AVOGARO A, MIOLA M, FAVARO A et al.: Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in Type 2 diabetic patients. Eur. J. Clin. Invest. (2001) 31:603-609.
39. TANIGUCHI A, FUKUSHIMA M, SAKAI M et al.: Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese japanese Type 2 diabetic patients. Metabolism (2001) 50:477-480.
40. TENENBAUM H, BEHAR S, BOYKO V et al.: Long-term effect of bezafibrate on pancreatic β-cell function and insulin resistance in patients with diabetes. Atherosclerosis (2006) [Epub ahead of print].
41. KEECH A, SIMES RJ, BARTER P et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 366:1849-1861.
42. RUBINS HB, ROBINS SJ, COLLINS D et al.: Diabetes, plasma insulin and cardiovascular disease: subgroup analysis from the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch. Intern. Med. (2002) 162:2597-2604.
43. DIABETES ATHEROSCLEROSIS INTERVENTION STUDY INVESTIGATORS: Effects of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet (2001) 357:905-910.
44. BROWN PJ, WINEGAR DA, PLUNKET KD et al.: A ureido-thiobutyric acid (GW9578) is a subtype-selective PPAR-α agonist with potent lipid-lowering activity. J. Med. Chem. (1999) 42:3785-3788.
45. HAWKE RL, CHAPMAN JM, WINEGAR DA et al.: Potent hypocholesterolemic activity of novel ureido phenoxyisobutyrates correlates with their intrinsic fibrate potency and not with their ACAT inhibitory activity. J. Lipid Res. (1997) 38:1189-1203.
46. MIYACHI H: Synthetic ligands for peroxisome proliferator-activated receptor-α, review of the patent literature 2000 - 2003. Expert Opin. Ther. Patents (2004) 14:607-618.
47. MIYACHI H, NOMURA M, TANASE T: Design, synthesis and evaluation of substituted phenylpropanoic amid derivatives as peroxisome proliferator activated receptor (PPAR) activators: novel human PPAR-α-selective activators. Bioorg. Med. Chem. Lett. (2002) 12:77-80.
48. YAMADA N, AKANUMA Y, KAWAMORI R et al.: K-111, a novel non-TZD insulin sensitizer, improves plasma glucose and lipid abnormalities in patients with drug-naive Type 2 diabetes mellitus (T2DM) ADA (2006) Washington Poster, Session (581-p).
49. SCHAEFER SA, FIAERING HU, YAMADA T et al.: K-111, a novel non-TZD insulin sensitizer improves glycaemic control without oedema or weight gain in treatment-naive patients with Type 2 diabetes mellitus (T2DM) ADA (2006) Washington Poster, Session (479-p).
50. LAYNE RD, SEHBAI AS, STARK LJ: Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy, Ann. Pharmacother. (2004) 38(2):232-234.
51. BARKER BJ, GOODENOUGH RR, FALKO JM: Fenofibrate monotherapy induced rhabdomyolysis. Diabetes Care (2003) 26(8):2482-2483.
52. DIERKES J, WESTPHAL S, LULEY C: Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet (1999) 354(9174):219-220.
53. LUC G, JACOB N, BOULY M et al.: Fenofibrate increases homocystinemia through a PPAR-α-mediated mechanism. J. Cardiovasc. Pharmacol. (2004); 43:452-453
54. GIRAL P, BRUCKERT E, JACOB N et al.: Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidaemia. Atherosclerosis (2001) 154:4221-4427.
55. TSIMIHODIMOS V, KAKAFIKA A, ELISAF M: Fibrate treatment can increase serum creatinine levels. Nephrol. Dial. Transplant. (2001) 16:1301.
56. LIPSCOMBE J, BARGMAN JM: Fibrate-induced increase in blood urea and creatinine. Nephrol. Dial. Transplant. (2001) 16:1515.
57. PARK CW, ZHANG Y, ZHANG X et al.: PPAR-α agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int. (2006) 69:1511-1517.
58. ANSQUER JC, FOUCHER C, RATTIER S et al.: Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in Type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am. J. Kidney Dis. (2005) 45:485-493.
59. SMULDERS YM, VAN EEDEN AE, STEHOUWER CD et al.: Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with noninsulin-dependent diabetes mellitus? Eur. J. Clin. Invest. (1997) 27:997-1002.
60. GUAN Y: Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J. Am. Soc. Nephrol. (2004); 15:2801-2815.
61. LEIBOWITZ MD, FIEVET C, HENNUYER N et al.: Activation of PPAR-δ alters lipid metabolism in db/db mice. FEBS Lett. (2000) 473:333-336.
62. BERGER J, LEIBOWITZ MD, DOEBBER TW et al.: Novel peroxisome proliferator-activated receptor (PPAR)-γ and PPAR-δ ligands produce distinct biological effects. J. Biol. Chem. (1999) 274:6718-6725.
63. BROWN PJ, SMITH-OLIVER TA, CHARIFSON PS et al.: Identification of peroxisome proliferator-activated receptor ligands from biased chemical libraries. Chem. Biol. (1997) 4:909-918.
64. OLIVER WR Jr, SHENK JL, SNAITH MR et al.: A selective peroxisome proliferator-activated receptor-δ agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA (2001) 98:5306-5311.
65. KRAMER DK, AL-KHALILI L, PERRINI S et al.: Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor-δ. Diabetes (2005) 54:1157-1163.
66. WULFF M, WINZELL MS, OLSEN GS et al.: The novel selective, partial PPAR-δ agonist NNC 61-5920 improves insulin sensitivity and increases FA-ox in skeletal muscles and in pancreatic β-cells in db/db mice. ADA (2006) Washington Poster, Session (580-p).
67. SOHDA T, MIZUNO K, TAWADA H et al.: Studies on antidiabetic agents. I. Synthesis of 5-[4-(2-methyl-2-phenyl-propoxy)-benzyl] thiazolidine-2,4-dione (AL-321) and related compounds. Chem. Pharm. Bull. (1982) 30:3563-3573.
68. CHANG AY, WYSE BM, GILCHRIST BJ et al.: Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/ob mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats. Diabetes (1983) 32:830-838.
69. LEHMANN JM, MOORE LB, SMITH-OLIVER TA et al.: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferators-activated receptor-γ (PPAR-γ). J. Biol. Chem. (1995) 270:12953-12956.
70. GOLDBERG RB, KENDALL DM, DEEG MA et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care (2005) 28:1547-1554.
71. DORMANDY JA, CHARBONNEL B, ECKLAND DA et al.: Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive study (PROspective Pioglitazone Clinical Trial In Macrovascular Events): a randomized controlled trial. Lancet (2005) 366:1279-1289.
72. CHENG AYY, FANTUS IG: Thiazolidinedione-induced congestive hart failure. Ann. Pharmacother. (2004) 38:817-820.
73. DIGMAN C, KLEIN AK, PITTAS AG: Leukopenia and thrombocytopenia caused by thiazolidinediones. Ann. Intern. Med. (2005) 143:465-466.
74. COLUCCIELLO M: Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch. Opthalmol. (2005) 123:1273-1275.
75. FONSECA V: Effect of chiazolidinediones on body weight in patients with diabetes mellitus. Am. J. Med. (2003) 115:42S-48S.
76. CHEN X, OSBORNE MC, RYBCZYNSKI PJ et al.: Pharmacological profile of a novel, non-TZD PPAR© agonist. Diabetes Obes. Metab. (2005) 7:536-546.
77. AHN JH, SHIN MS, JUNG SH et al.: Indenone derivatives: a novel template for peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists. J. Med. Chem. (2006) 49:4781-4784.
78. BLANC-DELMAS E, LEBEQUE N, WALLEZ V et al.: Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPAR-γ agonists. Bioorg. Med. Chem. (2006) [Epub ahead of print].
79. ARAKI K, YACHI M, HAGISAWA Y et al.: Antidiabetic characterization of CS-011: a new thiazolidinedione with potent insulin-sensitizing activity. Diabetes (2000) 49:105P.
80. SEBER S, UCAK S, BASAT O et al.: The effect of dual PPAR-α/γ stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in Type 2 diabetic patients. Diabetes Res. Clin. Pract. (2006) 71:52-58.
81. DEVASTHALE PV, CHEN S, JEON Y et al.: Design and synthesis of N-[(4-meth-oxyphenoxy)carbonyl]-N- 4-[2-(5-methyl-2-phenyl-4-oxazolyl) ethoxy]phenyl]-methyl]glycine [Muraglitazar/BMS-2985851, a novel peroxisome proliferator-activated receptor-α/γ dual agonist with efficacious glucose and lipid-lowering activities. J. Med. Chem (2005) 48:2248-2250.
82. HARRITY T, FARRELLY D, TIEMAN A et al.: Muraglitazar, a novel (α/γ) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves β-cell function in db/db mice. Diabetes (2006) 55:240-248.
83. BUSE JB, RUBIN CJ, FREDERICH R et al.: Muraglitazar, a dual (α/γ) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with Type 2 diabetes. Clin. Ther. (2005) 27:1181-1195.
84. KENDALL DM, RUBIN CJ, MOHIDEEN P et al.: Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with Type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care (2006) 29:1016-1023.
85. NISSEN SE, WOLSKI K, TOPOL EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with Type 2 diabetes mellitus. J. Am. Med. Assoc. (2005) 294:2581-2586.
86. FAGERBERG B, EDWARDS S, HALMOS T et al.: Tesaglitazar, a novel dual peroxisome proliferator-activated receptor-α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia. (2005) 48:1716-1725.
87. IMOTO H, SUGIYAMA Y, KIMURA H et al.: Studies on non-thiazolidinedione antidiabetic agents. 2. novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents. Chem. Pharm. Bull. (2003) 51:138-151.
88. FIEVET C, FRUCHART JC, STAELS B: PPAR-α and PPAR-γ dual agonists for the treatment of Type 2 diabetes and the metabolic syndrome. Curr. Opin. Pharmacol. (2006) [Epub ahead of print].
89. FRANCIS GA, ANNICOTTE JS, AUWERX J: PPAR agonists in the treatment of atherosclerosis. Curr. Opin. Pharmacol. (2003) 3:186-191.
90. WALLACE JM, SCHWARZ M, COWARD P et al.: Effects of peroxisome proliferator-activated receptor-α/δ agonists on HDL-cholesterol in vervet monkeys. J. Lipid Res. (2005) 46:1009-1016.
91. LIU KG, LAMBERT MH, LEESNITZER LM et al.: Identification of a series of PPAR-γ/δ dual agonists via solid-phase parallel synthesis. Bioorg. Med. Chem. Lett. (2001) 11:2959-2962.
92. TENENBAUM A, MOTRO M, FISMAN EZ: Dual and pan-peroxisome proliferator-activate receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc. Diabetol. (2005) 4:14.
93. UPTON R, WIDDOWSON PS, ISHII S et al.: Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555. Br. J. Pharmacol. (1998) 125:1708-1714.
94. ETGEN GJ, OLDHAM BA, JOHNSON WT et al.: A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-α/γ agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes (2002) 51:1083-1087.
95. GREGOIRE FM, RAKHMANOVA V, ZHANG F et al.: Effects of novel PPAR-δ, PPAR dual δ/γ, and PPAR-δ/γ/α (pan) agonists on PPAR-responsive genes in human adipocytes and macrophages. Diabetes (2005) 54:566P.
96. MAHINDROO N, WANG CC, LIAO CC et al.: Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology and molecular docking studies. J. Med. Chem. (2006) 49:1212-1216.
97. MAHINDROO N, HUANG CF, PENG YH et al.: Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology and biological activities. J. Med. Chem. (2005) 48:8194-8208.
98. MOGENSEN JP, JEPPESEN L, BURY PS: Design and synthesis of novel PPAR-α/γ/δ triple activators using a known PPAR-α/γ dual activator as structural template. Bioorg. Med. Chem. Lett. (2003) 13:257-260.
99. BRZOZOWSKI AM, PIKE AC, DAUTER Z et al.: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (1997) 389:753-758.
100. SMITH CL, O'MALLEY BW: Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. (2004) 25:45-71.
101. ROCCHI S, PICARD F. VAMECQ J et al.: A unique PPAR-γ ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell (2001) 8:737-747.
102. BERGER JP, PETRO AE, MACNAUL KL et al.: Distinct properties and advantages of a novel peroxisome proliferator-activated protein-γ selective modulator. Mol. Endocrinol. (2003) 17:662-676.
103. LIU K, BLACK RM, ACTON JJ et al.: Selective PPAR-γ modulators with improved pharmacological profiles. Bioorg. Med. Chem. Lett. (2005) 15:2437-2440.
104. ZHANG F, CLEMENS LE, GREGOIRE FM et al.: Metaglidasen, a novel selective peroxisome proliferator-activated receptor-γ modulator, preserves pancreatic islet structure and function in db/db mice. ADA (2006) Washington Poster, Session (1396-p).
105. MISRA P, CHAKRABARTI R, VIKRAMADITHYAN RK et al.: PAT5A: a partial agonist of peroxisome proliferator-activated receptor γ is a potent antidiabetic thiazolidinedione yet weakly adipogenic. J. Pharmacol. Exp. Ther. (2003) 306:763-771.
106. BURGERMEISTER E, SCHNOEBELEN A, FLAMENT A et al.: A novel partial agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ) recruits PPAR-γ-coactivaror-1γ, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol. Endocrinol. (2006) 20:809-830.
107. FUJIMURA T, SAKUMA H, KONISHI S et al.: FK614, a novel peroxisome protiferator-activated receptor-γ modulator, induces differential transactivation through a unique tigand-specific interaction with transcriptional coactivators. J. Pharmacol. Sci. (2005) 99:342-352.
108. LU IL, HUANG CF, PENG YH et al.: Structure-based drug design of a novel family of PPAR-γ partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. J. Med. Chem. (2006) 49:2703-2712.
109. KIM KR, LEE JH, KIM SJ et al.: KR-62980: a novel peroxisome proliferator-activated receptor-γ agonist with weak adipogenic effects. Biochem. Pharmacol. (2006) 72:446-454.
110. DUEZ H, LEFEBVRE B, POULAIN P et al.: Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated recepror-α modulation. Arterioscler. Thromb. Vasc. Biol. (2005) 25:585-591.
111. POURCET B, FRUCRART JC, STAELS B et al.: Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis. Expert Opin. Emerg. Drugs (2006) 11:379-401.
112. REIFEL-MILLER A, OTTO K, HAWKINS E et al.: A peroxisome proliferator-activated receptor-α/γ dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of Type 2 diabetes and dyslipidemia. Mol. Endocrinol. (245) 19:1593-1605.
113. OSTBERG T, SVENSSON S, SELEN G et al.: A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J. Biol Chem. (2004) 279:41124-41130.
114. MUKHERJEE R, HOENER PA, JOW L et aL: A selective peroxisome proliferator-activated receptor-γ (PPAR-γ) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol. Endocrinol. (2000) 14:1425-1433.
115. RIEUSSET J, TOURI F, MICHALIK L et al.: A new selective peroxisome proliferator-activated recepror-γ antagonist with antiobesity and antidiabetic activity. Mol. Endocrinol. (2002) 16:2628-2644.
116. FAJAS J, DEBRIL MB, AUVERX J: Peroxisome proliferator-activated receptor-γ: from adipogenesis to carcinogenesis. J. Mol. Endocrinol. (2001) 27:1-9.
117. HE TC, CHAN TA, VOGELSTEIN B et al.: PPAR-δ is an APC-regulated target of nonsteroidal anti-inflammarory drugs. Cell (1999) 99:335-345.
118. GUPTA RA, WANG D, KATKURI S et al.: Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nat. Med. (2004) 10:245-247.
119. WENG JR, CHEN CY, PINZONE JJ et al.: Beyond peroxisome proliferator-activated receptor-γ signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr. Relat. Cancer (2006) 13:401-413.
120. LAWRENCE JW, LI Y, CHEN S et al.: Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR)-α. PPAR-α fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression. J. Biol. Chem. (2001) 276:31521-31527.
121. BAUGHMAN TM, GRAHAM RA, WELLS-KNECHT K et al.: Metabolic activation of pioglitazone identified from rat and human liver microsomes and freshly isolated hepatocytes. Drug Metab. Dispos. (2005) 33:733-738.
122. ITO H, NAKANO A, KINOSHITA M et al: Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab. Invest. (2003) 83:1715-1721.
123. XU Y, GEN M, LU L et al.: PPAR-γ activation fails to provide myocardial protection in ischemia and reperfusion in pigs. Am. J. Physiol. Heart Circ. Physiol. (2005) 288:H11314-H11323.
124. GUAN Y, HAO C, CHA DR et al.: Thiazolidinediones expand body fluid volume through PPAR-γ stimulation of ENaC-mediated renal salt absorption. Nat. Med. (2005) 11:861-866.
125. RANGWALA SM, RHOADES B, SHAPIRO JS et al.: Generic modulation of PPAR-γ phosphorylation regulates insulin sensitivity. Dev. Cell (2003) 5:657-663.
126. PADWAL R, LAUPACIS A: Antihypertensive therapy and incidence of Type 2 diabetes: a systematic review. Diabetes Care (2004) 27:247-255.
127. SCHUPP M, CLEMENZ M, GINESTE R et al.: Molecular characterization of new selective peroxisome proliferator-activated receptor-γ modulators with angiotensin receptor blocking activity. Diabetes (2005) 54:3442-3452.
128. SCHUPP M, LEE LD, FROST N et al.: Regulation of peroxisome proliferator-activated receptor-γ activity by losartan metabolites. Hypertension (2006) 47:586-589.
129. HANSEN L, EKSTROM CT, TABANERA Y et al.: The Pro12Ala variant of the PPARG gene is a risk factor for PPAR-γ/α/agonist induced edema in Type 2 diabetic patients. J. Clin. Endocrinol. Metab. (2006) 91(9):3446-3450.
130. VESTERGAARD H, CLAUSEN J, BENEDIKTSSON R et al.: Insulin sensitivity and metabolic control in response to pioglitazone treatment differ between patients with Type 2 diabetes with and without the Pro12Ala variant in the PPAR-γ2 gene. ADA (2006) Washington Oral Presentation (321-OR).